In postmenopausal women with overweight or obesity receiving tirzepatide, use of MHT is associated with superior weight loss outcomes.

For postmenopausal women with overweight or obesity receiving tirzepatide, menopausal hormone therapy linked to increased weight loss.

Anti-diabetic and obesity drug, tirzepatide induced weight loss in obese mice and reduced growth of breast cancer tumors. | ...

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.